A NEW METHOD TO ASSAY DES-GAMMA-CARBOXYPROTHROMBIN - RESULTS OBTAINED IN 75 CASES OF HEPATOCELLULAR-CARCINOMA
A NEW METHOD TO ASSAY DES-GAMMA-CARBOXYPROTHROMBIN - RESULTS OBTAINED IN 75 CASES OF HEPATOCELLULAR-CARCINOMA
复制标题
DOI：
10.1016/s0016-5085(86)80025-7
复制
发表时间：
1986-11-01
期刊：
影响因子：
29.4
通讯作者：
LEFRERE, JJ
中科院分区：
文献类型：
--
作者：
SOULIER, JP;GOZIN, D;LEFRERE, JJ
描述了一种在未稀释的吸附血浆上使用葡萄球菌凝固酶来测定脱-γ-羧基凝血酶原(DCP)活性的新方法。在显色底物上测量形成的凝血酶-凝固酶，结果以对硝基苯胺释放后光密度每毫升增量的毫单位数表示。 96 名正常受试者的 DCP 水平低于 10 mU/ml（平均 3.58 mU/ml）。在 70 名未接受肝切除的肝细胞癌患者中，74% 的 DCP 水平升高至 20 至 420 mU/ml（大多数值在 20 至 100 mU/ml 之间）。去羧基凝血酶原和甲胎蛋白测量提供了补充信息，其中一种标记物在 87% 的肝细胞癌中呈阳性。 15 名转移性肝癌患者中有 14 名 DCP 水平正常，95 名肝硬化患者和 13 名慢性肝炎患者的 DCP 水平也正常。当“总因子II”水平低于40%时，建议在注射维生素K后5天进行第二次DCP测定，以排除任何维生素K缺乏（在肝细胞癌的情况下，DCP水平将保持升高）。对于诊断肝细胞癌，DCP 测定似乎比甲胎蛋白测定更灵敏且更特异：此外，两种测试是互补的。
A new method for assaying the activty of des-.gamma.-carboxyprothrombin (DCP), using staphylocoagulase on undiluted adsorbed plasma, is described. The thrombin-coagulase formed is measured on a chromogenic substrate, and the results are expressed in milliunits per millilater of increment of the optical density following the release of p-nitroaniline. Levels of DCP in 96 normal subjects were under 10 mU/ml (mean, 3.58 mU/ml). Of 70 nonhepatectomized patients with hepatocellular carcinomas, 74% had increased DCP levels of between 20 and 420 mU/ml (most of the values were between 20 and 100 mU/ml). Des-carboxyprothrombin and .alpha.-fetoprotein measurements gave complementary information, one marker or the other being positive in 87% of hepatocellular carcinoma. Fourteen of 15 patients with metastatic carcinoma of the liver had normal DCP levels, as did 95 patients with liver cirrhosis and 13 patients with chronic hepatitis. When the level of "total factor II" is below 40%, it is recommended that a second determination of DCP be performed 5 days after the injection of vitamin K, to exclude any vitamin K deficiency (in the case of hepatocellular carcinoma the DCP level will remain elevated). The DCP assay appears more sensitive and more specific than the .alpha.-fetoprotein assay for the diagnosis of hepatocellular carcinoma: furthermore, both tests are complementary.